Scott Edmondson leaves AstraZeneca, starts new chapter at Nimbus; With IPO filed, Taysha pulls together an AveXis-heavy team
→ Nimbus Therapeutics, which identified 4 new targets – AMPKβ2, CTPS1, Cbl-b and WRN – in their drug discovery efforts, has reeled in a big fish with Big Pharma vet Scott Edmondson now a part of the mix as SVP, head of chemistry. Edmondson had been AstraZeneca’s director and head of Boston oncology chemistry for almost 4 years.
From 1998-2016, Edmondson was at Merck and worked his way up to director of discovery chemistry. While at the pharma giant, he discovered vibegron for patients with overactive bladder, a drug that Urovant would pick up in 2017. Urovant filed for an NDA for vibegron at the FDA, which the agency accepted for review in March.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
